Prediction of Immune Infiltration Level and Immunotherapy Efficacy of Esophageal Squamous Cell Carcinoma Based on Multimodal Deep Learning
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 110
- 试验地点
- 1
- 主要终点
- Immunogene signatures with predictive value for immunotherapy of ESCC
研究概览
简要总结
The burden of esophageal squamous cell carcinoma (ESCC) in China is substantial, with 85% of the cancers being in the progressive stage. The treatment for advanced ESCC are extremely limited, and immunotherapy, represented by PD-1 inhibitors, has demonstrated a promising application potential. However, the effectiveness of PD-1 inhibitors varies significantly among patients with different types of ESCC, and currently, there is no effective method to predict the response to PD-1 inhibitors. In this study, investigators aim to construct a multimodal deep learning-based model to predict the level of immune infiltration and the efficacy of immunotherapy for ESCC, integrating both pathological image features and clinical information of patients with ESCC, thereby enhancing the level of individualized and precise treatment for ESCC.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Availability of Hematoxylin and Eosin (H&E) stained images, molecular data obtained through RNA sequencing (RNA-Seq, DNA-seq), and comprehensive clinical information including patient age, gender, history of alcohol consumption, history of smoking, AJCC Tumor, Node, Metastasis Stage, specific location of oesophageal cancer occurrence, and history of reflux.
- •The sample collection is restricted to cancerous tissue, encompassing both primary tumor samples and those from metastatic sites.
排除标准
- •Patients diagnosed with adenosquamous carcinoma or presenting with a combination of other types of oesophageal cancers;
- •Cases involving combined adenocarcinoma affecting the gastroesophageal junction;
- •Individuals with high-grade tumors that have not penetrated the basement membrane, as confirmed by postoperative pathological examination;
- •Subjects in whom postoperative pathology confirms an absence of residual malignant tissue.
结局指标
主要结局
Immunogene signatures with predictive value for immunotherapy of ESCC
时间窗: After undergoes surgery.
次要结局
- Prognosis and immunotherapy tolerance in ESCC patients(Follow-up for at least 1 year after undergoing surgery)
研究者
Wangluowei
M.D., PhD., Doctoral supervisor, Professor, Chief physician
Changhai Hospital